Immune modulation as a therapeutic strategy for non-small-cell lung cancer

Clinical Lung Cancer

Volumn 9, Issue SUPPL. 1, 2008, Pages

  Holt, Gregory E ^a   Disis, Mary L ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Cytokines; Epitope; Immunogenic agents; MUC1; Tumor antigens; Vaccine therapy

Indexed keywords

ANNEXIN; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; CYTOKINE; EPITOPE; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; INTERLEUKIN 12; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR ANTIGEN;

ANTIGEN PRESENTING CELL; CANCER CELL; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; FOLLOW UP; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; INJECTION SITE REACTION; LUNG NON SMALL CELL CANCER; MAJOR HISTOCOMPATIBILITY COMPLEX; MUTAGENESIS; NONHUMAN; OVERALL SURVIVAL; REVIEW; RISK ASSESSMENT; SKIN MANIFESTATION; SURVIVAL RATE; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE;

EID: 40449118293     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2008.s.003     Document Type: Article

References (80)

1. American Cancer Society Web site. Cancer Facts & Figures Available at: http://www.cancer.org/downloads/stt/CFF2007EstCsDths07.pdf 2007 Accessed: December 15, 2007.
2. H Sugimura FC Nichols P Yang Survival after recurrent nonsmall-cell lung cancer after complete pulmonary resection Ann Thorac Surg 83 2007 409 418
3. CT Salerno S Frizelle GA Niehans Detection of occult micrometastases in non-small cell lung carcinoma by reverse transcriptase-polymerase chain reaction Chest 113 1998 1526 1532
4. BJ Braakhuis MP Tabor JA Kummer A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications Cancer Res 63 2003 1727 1730
5. Y Oji S Miyoshi H Maeda Overexpression of the Wilm's tumor gene WT1 in de novo lung cancers Int J Cancer 100 2002 297 303
6. S Hammerstrom The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues Semin Cancer Biol 9 1999 67 81
7. N Yoshida H Abe T Ohkuri Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non-small cell lung carcinoma and their prognostic significance Int J Oncol 28 2006 1089 1098
8. C Uyttenhove J Maryanski T Boon Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression J Exp Med 157 1983 1040 1052
9. JL Urban RC Burton JM Holland Mechanisms of syngeneic tumor rejection. susceptibility of host-selected progressor variants to various immunological effector cells J Exp Med 155 1982 557 573
10. H Wang DD Eckels Mutations in immunodominant T cell epitopes derived from the nonstructural 3 protein of hepatitis C virus have the potential for generating escape variants that may have important consequences for T cell recognition J Immunol 162 1999 4177 4183
11. R Wallich N Bulbuc GJ Hammerling Abrogation of metastatic properties of tumour cells by de novo expression of H-2K antigens following H-2 gene transfection Nature 315 1985 301 305
12. K Hui F Grosveld H Festenstein Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation Nature 311 1984 750 752
13. J Wierecky MR Mueller S Wirths Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients Cancer Res 66 2006 5910 5918
14. CB Guo S Wang C Deng Relationship between matrix metalloproteinase 2 and lung cancer progression Mol Diagn Ther 11 2007 183 192
15. NH Cho ES Koh DW Lee Comparative proteomics of pulmonary tumors with neuroendocrine differentiation J Proteome Res 5 2006 643 650
16. T Peikert U Specks C Farver Melanoma antigen A4 is expressed in nonsmall cell lung cancers and promotes apoptosis Cancer Res 66 2006 4693 4700
17. R Salgia T Lynch A Skarin Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non–small-cell lung carcinoma J Clin Oncol 21 2003 624 630
18. J Nemunaitis D Sterman D Jablons Granulocyte–macrophage colonystimulating factor gene-modified autologous tumor vaccines in non–small-cell lung cancer J Natl Cancer Inst 96 2004 326 331
19. J Nemunaitis T Jahan H Ross Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAXs vaccine in advanced-stage non-small-cell lung cancer Cancer Gene Ther 13 2006 555 562
20. I Bolonaki A Kotsakis E Papadimitraki Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide J Clin Oncol 25 2007 2727 2734
21. PF Brunsvig S Aamdal MK Gjertsen Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer Cancer Immunol Immunother 55 2006 1553 1564
22. C Butts N Murray A Maksymiuk Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non–small-cell lung cancer J Clin Oncol 23 2005 6674 6681
23. K Kontani O Taguchi Y Ozaki Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin Int J Mol Med 12 2003 493 502
24. GY Ishioka J Fikes G Hermanson Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes J Immunol 162 1999 3915 3925
25. MA Morse TM Clay AC Hobeika Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules Clin Cancer Res 11 2005 3017 3024
26. C Rochlitz R Robert Figlin P Squiban Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer J Gene Med 5 2003 690 699
27. JA Wolff RW Malone P Williams Direct gene transfer into mouse muscle in vivo Science 247 1990 1465 1468
28. D Maurer G Stingl Dendritic cells in the context of skin immunity MT Lotze AW Thompson Dendritic Cells First ed. 1999 Academic Press New York 111 122
29. JS Boyle A Silva JL Brady DNA immunization: induction of higher avidity antibody and effect of route on T cell cytotoxicity Proc Natl Acad Sci U S A 94 1997 14626 14631
30. SA Thomson MA Sherritt J Medveczky Delivery of multiple CD8 cytotoxic T cell antigenic determinants J Immunol 160 1998 1717 1723
31. MP Velders S Weijzen GL Eiben Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine J Immunol 166 2001 5366 5373
32. JR Greenland NL Letvin Chemical adjuvants for plasmid DNA vaccines Vaccine 25 2007 3731 3741
33. JJ Kim NN Trivedi LK Nottingham Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens Eur J Immunol 28 1998 1089 1103
34. DH Barouch S Santra K Tenner-Racz Potent CD4+ T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSF J Immunol 168 2002 562 568
35. AD Bins A Jorritsma MC Wolkers A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression Nat Med 11 2005 899 904
36. RD Cassaday PM Sondel M David A phase I study of immunization using particle-mediated epidermal delivery of genes for gp100 and GM-CSF into uninvolved skin of melanoma patients Clin Cancer Res 13 2007 540 549
37. LE Johnson TP Frye N Chinnasamy Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cells Cancer Immunol Immunother 56 2007 885 895
38. JS Robertson E Griffiths Assuring the quality, safety, and efficacy of DNA vaccines Mol Biotechnol 17 2001 143 149
39. L Fong Y Hou A Rivas Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy Proc Natl Acad Sci U S A 98 2001 8809 8814
40. T Itoh Y Ueda I Kawashima Immunotherapy of solid cancer using dendritic cells pulsed with the HLA-A24-restricted peptide of carcinoembryonic antigen Cancer Immunol Immunother 51 2002 99 106
41. B Chan W Lee CX Hu Adoptive cellular immunotherapy for non-small cell lung cancer: a pilot study Cytotherapy 5 2003 46 54
42. T Mine R Gouhara N Hida Immunological evaluation of CTL precursororiented vaccines for advanced lung cancer patients Cancer Sci 94 2003 548 556
43. LE Raez PA Cassileth JJ Schlesselman Induction of CD8 T-cell-Ifn-c response and positive clinical outcome after immunization with gene-modified allogeneic tumor cells in advanced non-small-cell lung carcinoma Cancer Gene Ther 10 2003 850 858
44. Y Oka A Tsuboi T Taguchi Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression Proc Natl Acad Sci U S A 101 2004 13885 13890
45. A Tsuboi Y Oka T Osaki WT1 peptide-based immunotherapy for patients with lung cancer: report of two cases Microbiol Immunol 48 2004 175 184
46. Y Ueda T Itoh I Nukaya Dendritic cell-based immunotherapy of cancer with carcinoembryonic antigen-derived, HLA-A24-restricted CTL epitope: clinical outcomes of 18 patients with metastatic gastrointestinal or lung adenocarcinoma Int J Oncol 24 2004 909 917
47. MA Morse J Garst T Osada A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer J Transl Med 3 2005 9
48. J Nemunaitis RO Dillman PO Schwarzenberger Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non–small-cell lung cancer J Clin Oncol 24 2006 4721 4730
49. G González T Crombet E Neninger Therapeutic vaccination with epidermal growth factor (EGF) in advanced lung cancer Hum Vaccin 3 2007 8 13
50. JI Mayordomo R Andres MD Isla Results of a pilot trial of immunotherapy with dendritic cells pulsed with autologous tumor lysates in patients with advanced cancer Tumori 93 2007 26 30
51. RG Meyer S Korn P Micke An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer Lung Cancer 58 2007 88 94
52. M von Mehren P Arlen J Gulley The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma Clin Cancer Res 7 2001 1181 1191
53. LA Small DM Da Silva KE de Visser A murine model for the effects of pelvic radiation and cisplatin chemotherapy on human papillomavirus vaccine efficacy Clin Cancer Res 7 3 suppl 2001 876s 881s
54. ES Bergmann-Leitner SI Abrams Treatment of human colon carcinoma cell lines with anti-neoplastic agents enhances their lytic sensitivity to antigen-specific CD8+ cytotoxic T lymphocytes Cancer Immunol Immunother 50 2001 445 455
55. RE Merritt A Mahtabifard RE Yamada Cisplatin augments cytotoxic Tlymphocyte-mediated antitumor immunity in poorly immunogenic murine lung cancer J Thorac Cardiovasc Surg 126 2003 1609 1617
56. CT Garnett C Palena M Chakraborty Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes Cancer Res 64 2004 7985 7994
57. AK Nowak BW Robinson RA Lake Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors Cancer Res 63 2003 4490 4496
58. W Qi X Liu D Qiao Isoform-specific expression of 14-3-3 proteins in human lung cancer tissues Int J Cancer 113 2005 359 363
59. SR Pereira-Faca R Kuick E Puravs Identification of 14-3-3 theta as an antigen that induces a humoral response in lung cancer Cancer Res 67 2007 12000 12006
60. EF Patz Jr MJ Campa EB Gottlin Panel of serum biomarkers for the diagnosis of lung cancer J Clin Oncol 25 2007 5578 5583
61. FM Brichory DE Misek AM Yim An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer Proc Natl Acad Sci U S A 98 2001 9824 9829
62. C Luo X Xiao D Liu CABYR is a novel cancer-testis antigen in lung cancer Clin Cancer Res 13 2007 1288 1297
63. S Park Y Lim D Lee Identification and characterization of a novel cancer/testis antigen gene CAGE-1 Biochim Biophys Acta 1625 2003 173 182
64. CJ Chapman A Murray McElveen Autoantibodies in lung cancer - possibilities for early detection and subsequent cure Thorax 2007 Epub ahead of print.
65. JL Broers J Viallet SM Jensen Expression of c-myc in progenitor cells of the bronchopulmonary epithelium and in a large number of non-small cell lung cancers Am J Respir Cell Mol Biol 9 1993 33 43
66. JC Soria SJ Jang FR Khuri Overexpression of cyclin B1 in early-stage nonsmall cell lung cancer and its clinical implication Cancer Res 60 2000 4000 4004
67. AM Egloff LA Vella OJ Finn Cyclin B1 and other cyclins as tumor antigens in immunosurveillance and immunotherapy of cancer Cancer Res 66 2006 6 9
68. T Fukuyama T Hanagiri M Takenoyama Identification of a new cancer/germline gene, KK-LC-1, encoding an antigen recognized by autologous CTL induced on human lung adenocarcinoma Cancer Res 66 2006 4922 4928
69. Y Watanabe S LePage M Elliot Characterization of preexisting humoral immunity specific for two cancer-testis antigens overexpressed at the mRNA level in non-small cell lung cancer Cancer Immun 6 2006 3
70. H Hariu Y Hirohashi T Torigoe Aberrant expression and potency as a cancer immunotherapy target of inhibitor of apoptosis protein family, Livin/ML-IAP in lung cancer Clin Cancer Res 11 2005 1000 1009
71. N Yoshida H Abe Ohkuri Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non-small cell lung carcinoma and their prognostic significance Int J Oncol 28 2006 1089 1098
72. C Groeper F Gambazzi P Zajac Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer Int J Cancer 120 2007 337 343
73. H Sasaki H Yukiue S Moriyama Expression of the protein gene product 9.5, PGP9.5, is correlated with T-status in non-small cell lung cancer Jpn J Clin Oncol 31 2001 532 535
74. F Brichory D Beer F Le Naour Proteomics-based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer Cancer Res 61 2001 7908 7912
75. Y Ichiki T Hangagiri M Takenoyama Tumor specific expression of survivin-2B in lung cancer as a novel target of immunotherapy Lung Cancer 48 2005 281 289
76. M Sugaya M Takenoyama Y Shigematsu Identification of HLA-A24 restricted shared antigen recognized by autologous cytotoxic T lymphocytes from a patient with large cell carcinoma of the lung Int J Cancer 120 2007 1055 1062
77. L Zhang J Liu H Zhang Discovery and identification of anti-U1-A snRNP antibody in lung cancer Sci China C Life Sci 48 2005 641 647
78. G Chen X Wang J Yu Autoantibody profiles reveal ubiquilin 1 as a humoral immune response target in lung adenocarcinoma Cancer Res 67 2007 3461 3467
79. K Nakagawa Y Noguchi Uenaka XAGE-1 expression in non-small cell lung cancer and antibody response in patients Clin Cancer Res 11 2005 5496 5503
80. M Shimono A Uenaka Y Noguchi Identification of DR9-restricted XAGE antigen on lung adenocarcinoma recognized by autologous CD4 T-cells Int J Oncol 30 2007 835 840